502 related articles for article (PubMed ID: 34778797)
1. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
[TBL] [Abstract][Full Text] [Related]
2. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
[TBL] [Abstract][Full Text] [Related]
3. Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies.
Greenberger LM; Saltzman LA; Gruenbaum LM; Xu J; Reddy ST; Senefeld JW; Johnson PW; Fields PA; Sanders C; DeGennaro LJ; Nichols GL
Blood Cancer Discov; 2022 Nov; 3(6):481-489. PubMed ID: 36074641
[TBL] [Abstract][Full Text] [Related]
4. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
5. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
[TBL] [Abstract][Full Text] [Related]
6. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
7. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
8. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.
Keppler-Hafkemeyer A; Greil C; Wratil PR; Shoumariyeh K; Stern M; Hafkemeyer A; Ashok D; Hollaus A; Lupoli G; Priller A; Bischof ML; Ihorst G; Engelhardt M; Marks R; Finke J; Bertrand H; Dächert C; Muenchhoff M; Badell I; Emmerich F; Halder H; Spaeth PM; Knolle PA; Protzer U; von Bergwelt-Baildon M; Duyster J; Hartmann TN; Moosmann A; Keppler OT
Nat Cancer; 2023 Jan; 4(1):81-95. PubMed ID: 36543907
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
Jiménez M; Roldán E; Fernández-Naval C; Villacampa G; Martinez-Gallo M; Medina-Gil D; Peralta-Garzón S; Pujadas G; Hernández C; Pagès C; Gironella M; Fox L; Orti G; Barba P; Pumarola T; Cabirta A; Catalá E; Valentín M; Marín-Niebla A; Orfao A; González M; Campins M; Ruiz-Camps I; Valcárcel D; Bosch F; Hernández M; Crespo M; Esperalba J; Abrisqueta P
Blood Adv; 2022 Feb; 6(3):774-784. PubMed ID: 34844263
[TBL] [Abstract][Full Text] [Related]
12. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
[TBL] [Abstract][Full Text] [Related]
15. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
16. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
17. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
19. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S; Hofsink Q; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Zweegman S; Kater AP; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; Beaumont T; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
JAMA Oncol; 2022 Oct; 8(10):1477-1483. PubMed ID: 35951338
[TBL] [Abstract][Full Text] [Related]
20. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
